Class Action Lawsuit Filed Against Iovance Biotherapeutics, Investors Alerted

Investor Alert: Class Action Against Iovance Biotherapeutics



On July 7, 2025, Pomerantz LLP announced the filing of a class action lawsuit against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). This legal action concerns allegations of securities fraud and other misconduct by certain officers and directors of the company. The class action primarily involves investors who incurred losses through their investments in Iovance during the specific class period.

Understanding the Class Action


If you are one of the investors who faced losses from Iovance's securities, it’s crucial to act promptly. To be eligible for participation as a Lead Plaintiff in this case, you must file a request by July 14, 2025, and provide pertinent personal details such as your mailing address and the number of shares purchased.

Financial Turmoil at Iovance


The backdrop of this lawsuit stems from an unsettling financial disclosure made by Iovance on May 8, 2025. After the market closed, the company announced its first-quarter results revealing a staggering drop in total product revenue—from $73.7 million in the previous quarter to $49.3 million. This massive decline was compounded further with a grim revenue forecast for the entire fiscal year of 2025, which was slashed from an expected $450 million - $475 million to a revised estimate of only $250 million - $300 million. This reduction exceeds a dramatic 40% at the midpoint.

Iovance explained that the downward revision of revenue guidance was influenced by recent dynamics related to the launch of its lead product candidate, Amtagvi. Furthermore, the company noted that its updated forecast takes into account the growth trajectories and treatment timelines observed for new authorized treatment centers (ATCs). This alarming news led to a precipitous drop in Iovance’s stock, which plummeted by $1.42 per share, equating to a 44.79% decrease, closing the next trading day at just $1.75 per share.

The Role of Pomerantz LLP


Pomerantz LLP is known for its prominent involvement in corporate and securities class litigation. The firm, established over 85 years ago, is recognized as one of the leaders in the field and has taken on numerous high-profile cases. With offices in major cities around the globe, including New York, London, Paris, and Tel Aviv, Pomerantz has a rich history of advocating for victims of corporate wrongdoing. The firm has successfully recovered significant damages for class members in past cases, underscoring its status in the legal landscape.

For investors with questions or those wishing to discuss their experiences with Iovance, Pomerantz welcomes inquiries. Danielle Peyton can be contacted directly at 646-581-9980 or through the firm's website. Interested parties are strongly advised to not wait until the deadline, as the window to claim rights under the class action is closing soon.

What This Means for Investors


The class action lawsuit against Iovance serves as a vital reminder about the potential risks inherent in investing in publicly traded companies, especially in sectors involving therapeutic products. The decline in stock value and the ensuing class action may raise caution flags among both existing and prospective investors. It highlights the critical nature of transparency and the duty of corporate executives to provide accurate and timely information to shareholders.

In summary, if you have suffered losses in Iovance due to the allegations of securities fraud, it’s important to consider participation in the class action initiated by Pomerantz. Protect your investments by staying informed and acting quickly as the deadlines approach.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.